Navigation Links
Researchers pinpoint possible new cause for unexplained miscarriages
Date:11/1/2011

TORONTO, ON., Nov. 1, 2011Researchers at St. Michael's Hospital have identified a potential new cause for unexplained miscarriages in mice.

They also identified two possible treatments to prevent these miscarriages and their work has broader implications for the development of new drugs to treat heart attacks and strokes.

The researchers, led by Dr. Heyu Ni, found that the same kind of blood-clotting in coronary arteries or blood vessels in the brain that causes heart attacks and strokes also happens in the placenta. The massive clotting can destroy the placenta, block blood flow to the fetus and cause miscarriages.

This condition is known as fetal and neonatal immune thrombocytopenia (FNIT), a bleeding disorder in which mothers generate antibodies that attack and destroy platelets in their fetuses and newborns. Platelets are the small cells in the blood that play a key role in clotting. In severe cases, FNIT may lead to bleeding in the brains of the fetuses and newborns and cause neurological impairment or even death.

The condition affects between one in 800 and one in 1,500 live births and is more commonly reported among Caucasians.

Maternal antibodies to one specific platelet antigen, HPA-1 (human platelet antigen) cause 75-95 per cent of FNIT cases. Antigens are the proteins that antibodies attack because they think they are a foreign substance such as bacteria or a virus.

Dr. Ni and his team discovered a novel mechanism that might partially explain this problem. They found that another antigen, HPA-2, causes a type of FNIT never described before that can lead to miscarriages in more than 83 per cent of mice. There have been only six to eight reported live births in the world of humans with FNIT caused by HPA-2. The new research suggests the reason these cases appear to be so rare is that most of the affected fetuses died through miscarriages, before doctors examined them.

Dr. Conglei Li and other researchers in Dr. Ni's laboratory found that sometimes these antibodies not only destroy platelets, but activate them and cause massive clotting in the placentas.

Dr. Ni, an immunologist, is also a scientist with Canadian Blood Services (CBS), one of the funders of this research. His findings appear in the November issue of the prestigious Journal of Clinical Investigation.

Dr. Ni's group demonstrated that, in mice, these miscarriages can be prevented using at least two therapies. One is the transfusion of IgG (IVIG), a CBS product made from plasma from donated blood, which has been widely used to treat several autoimmune diseases. The other is the transfusion of an antibody known as anti-FcRn, which blocks the attacking maternal antibodies from crossing the placenta. This second method was developed by Dr. Ni's group.

"Fifty per cent of pregnancies do not end in a live birth. Our findings may help explain why some women are having miscarriages," said Dr. Ni. "Furthermore, our treatments could be the answer to carrying a healthy child to term."

The observations by Dr. Ni's team of platelet activation and enhancement of clotting may be important in the development of safer anti-thrombotic drugs. These drugs are under development by several companies.

Dr. Ni's group is now collaborating with clinicians to address how relevant these discoveries in mice are in humans.


'/>"/>

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital
Source:Eurekalert

Related biology news :

1. Savannas, forests in a battle of the biomes, Princeton researchers find
2. Lung regeneration closer to reality with new discovery by Weill Cornell Medical College researchers
3. Researchers build largest protein interaction map to date
4. WSU researchers demonstrate rare animal model for studying depression
5. UC Davis researchers discover complexities of DNA repair
6. Researchers generate first complete 3-D structures of bacterial chromosome
7. Researchers at NYU Langone Medical Center review the microbiome and its possible role in cancers
8. Researchers discover that same gene has opposite effects in prostate, breast cancers
9. Researchers do precise gene therapy without a needle
10. Researchers explore planktons shifting role in deep sea carbon storage
11. Stanford researchers examine impact of green politics on recent national elections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/13/2016)... , January 13, 2016 ... published a new market report titled - Biometric Sensors Market ... Forecast, 2015 - 2023. According to the report, the global biometric ... is anticipated to reach US$1,625.8 mn by 2023, expanding ... In terms of volume, the biometric sensors market is ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... ... 04, 2016 , ... Franz Inc. , an early ... has been recognized As “ Best in Semantic Web Technology - USA & ... America, it’s our priority to showcase prominent professionals who are excelling in their ...
(Date:2/3/2016)... SAN DIEGO , Feb. 3, 2016 /PRNewswire/ ... medicine company with the first pluripotent stem cell-derived ... 1 diabetes in clinical-stage development, today announced that ... Janssen Pharmaceutical Companies of Johnson & Johnson, have ... BetaLogics group into ViaCyte.  The agreement provides ViaCyte ...
Breaking Biology Technology: